Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Michelle B. Kim, Kyle E. Giesler, Yesim A. Tahirovic, Valarie M. Truax, Dennis C. Liotta & Lawrence J. Wilson. (2016) CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. Expert Opinion on Investigational Drugs 25:12, pages 1377-1392.
Read now
Read now
Rumiko Shimazawa & Masayuki Ikeda. (2016) Drug–diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics 16:2, pages 187-204.
Read now
Read now
Mayte Pérez-Olmeda & José Alcami. (2013) Determination of HIV tropism and its use in the clinical practice. Expert Review of Anti-infective Therapy 11:12, pages 1291-1302.
Read now
Read now
Jose V Fernandez-Montero, Eugenia Eugenia, Pablo Barreiro, Pablo Labarga & Vicente Soriano. (2013) Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management. Expert Opinion on Drug Safety 12:5, pages 697-707.
Read now
Read now
Gabriel Rebick & Sharon L Walmsley. (2012) Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. Virus Adaptation and Treatment 4, pages 51-63.
Read now
Read now
Kenji Maeda, Debananda Das, Hirotomo Nakata & Hiroaki Mitsuya. (2012) CCR5 inhibitors: emergence, success, and challenges. Expert Opinion on Emerging Drugs 17:2, pages 135-145.
Read now
Read now
Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg & Bruce R. Schackman. (2012) Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clinical Trials 13:1, pages 1-10.
Read now
Read now
Articles from other publishers (50)
Marlon Liyanage, Mina Nikanjam, Lynn McFadyen, Manoli Vourvahis, Luise Rogg, John Moye, Ellen G. Chadwick, Patrick Jean-Philippe, Mark Mirochnick, Kyle Whitson, Sarah Bradford, Edmund V. Capparelli & Brookie M. Best. (2022) Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Pediatric Infectious Disease Journal 41:11, pages 885-890.
Crossref
Crossref
Ashley O. Otto, Christina G. Rivera, John D. Zeuli & Zelalem Temesgen. (2021) Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells 10:5, pages 1263.
Crossref
Crossref
Julia C. Rosebush, Brookie M. Best, Ellen G. Chadwick, Kevin Butler, John Moye, Elizabeth Smith, Sarah Bradford, Christina A. Reding, Sisinyana R. Mathiba, Sherika Hanley, Mariam Aziz, James Homans, Edward P. Acosta, William Murtaugh, Manoli Vourvahis, Lynn Mcfadyen, Katy Hayward, Mark Mirochnick & Pearl Samson. (2021) Pharmacokinetics and safety of maraviroc in neonates. AIDS 35:3, pages 419-427.
Crossref
Crossref
Andrea De Luca, Patrizio Pezzotti, Charles Boucher, Matthias Döring, Francesca Incardona, Rolf Kaiser, Thomas Lengauer, Nico Pfeifer, Eugen Schülter, Anne-Mieke Vandamme, Maurizio Zazzi & Anna Maria Geretti. (2019) Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. PLOS ONE 14:11, pages e0225381.
Crossref
Crossref
Tianwen Li & Jianhong Zhu. (2019) Entanglement of CCR5 and Alzheimer’s Disease. Frontiers in Aging Neuroscience 11.
Crossref
Crossref
Alison C. Savage, Lee M. Tatham, Marco Siccardi, Trevor Scott, Manoli Vourvahis, Andrew Clark, Steve P. Rannard & Andrew Owen. (2019) Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 138, pages 30-36.
Crossref
Crossref
Lee M. Tatham, Alison C. Savage, Andrew Dwyer, Marco Siccardi, Trevor Scott, Manoli Vourvahis, Andrew Clark, Steven P. Rannard & Andrew Owen. (2019) Towards a Maraviroc long-acting injectable nanoformulation. European Journal of Pharmaceutics and Biopharmaceutics 138, pages 92-98.
Crossref
Crossref
Paolo Maggi, Antonio Di Biagio, Stefano Rusconi, Stefania Cicalini, Maurizio D’Abbraccio, Gabriella d’Ettorre, Canio Martinelli, Giuseppe Nunnari, Laura Sighinolfi, Vincenzo Spagnuolo & Nicola Squillace. (2017) Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infectious Diseases 17:1.
Crossref
Crossref
Sergio Serrano-Villar, Giorgia Caruana, Alexander Zlotnik, José A. Pérez-Molina & Santiago Moreno. (2017) Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy 61:12.
Crossref
Crossref
C Dentone, G Sterrantino, A Signori, G Cenderello, M Guerra, P De Leo, V Bartolacci, E Mantia, G Orofino, M Giacomini, B Bruzzone, D Francisci & A Di Biagio. (2017) Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. International Journal of STD & AIDS 28:11, pages 1067-1073.
Crossref
Crossref
Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, Nataliya Brima, Andrew Copas, Amanda Clarke, Martin Fisher, Gabriel Schembri, David Hawkins, Andy Williams & Richard Gilson. (2017) Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial). Journal of Antimicrobial Chemotherapy 72:6, pages 1760-1768.
Crossref
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Crossref
Victor G. Kramer & Mark A. Wainberg. 2017. Handbook of Antimicrobial Resistance. Handbook of Antimicrobial Resistance
499
521
.
Douglas D. Richman, Richard J. Whitley & Frederick J. HaydenChristine J. Kubin, Barbara S. Taylor & Scott M. Hammer. 2016. Clinical Virology. Clinical Virology
169
214
.
Ildefonso PulidoMiguel GenebatAna I. Alvarez-RiosRebeca S. De Pablo-BernalMohammed Rafii-El-Idrissi BenhniaYolanda M. PachecoEzequiel Ruiz-MateosManuel Leal. (2016) Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients. Viral Immunology 29:8, pages 471-477.
Crossref
Crossref
Nicole Hassoun. (2015) The Global Health Impact Index: Promoting Global Health. PLOS ONE 10:12, pages e0141374.
Crossref
Crossref
E Pedrol, JM Llibre, M Tasias, A Currán, JM Guardiola, E Deig, A Guelar, O Martínez-Madrid, L Tikhomirova & R Ramírez. (2015) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Medicine 16:10, pages 628-634.
Crossref
Crossref
Joanna Kryst, Paweł Kawalec & Andrzej Pilc. (2015) Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLOS ONE 10:5, pages e0124279.
Crossref
Crossref
Victor G Kramer & Mark A Wainberg. (2015) Resistance against inhibitors of HIV-1 entry into target cells. Future Virology 10:2, pages 97-112.
Crossref
Crossref
Frederick J. Lee & Andrew Carr. 2015. Dyslipidemias. Dyslipidemias
155
176
.
M Parczewski, A Urbańska, K Maciejewska, J Clark & M Leszczyszyn-Pynka. (2014) Association of chemokine receptor gene variants with HIV-1 genotype predicted tropism. HIV Medicine, pages n/a-n/a.
Crossref
Crossref
David A. Cooper, Jayvant Heera, Prudence Ive, Mariette Botes, Edwin Dejesus, Robert Burnside, Nathan Clumeck, Sharon Walmsley, Adriano Lazzarin, Geoffrey Mukwaya, Michael Saag & Elna van Der Ryst. (2014) Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1. AIDS 28:5, pages 717-725.
Crossref
Crossref
Simbarashe Takuva, Mhairi Maskew, Alana T Brennan, Lawrence Long, Ian Sanne & Matthew P Fox. (2014) Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. Journal of the International AIDS Society 17:1, pages 18651.
Crossref
Crossref
Victor G. Kramer & Mark A. Wainberg. 2014. Handbook of Antimicrobial Resistance. Handbook of Antimicrobial Resistance
1
21
.
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Pierre Corbeau. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine
1
26
.
Laure Surgers & Karine Lacombe. (2013) Hepatoxicity of new antiretrovirals: A systematic review. Clinics and Research in Hepatology and Gastroenterology 37:2, pages 126-133.
Crossref
Crossref
Calvin J. Cohen, Jean-Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, Laurence Rimsky, Simon Vanveggel, Peter Williams & Katia Boven. (2013) Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 27:6, pages 939-950.
Crossref
Crossref
Timothy J Henrich & Daniel R Kuritzkes. (2013) HIV-1 entry inhibitors: recent development and clinical use. Current Opinion in Virology 3:1, pages 51-57.
Crossref
Crossref
Yuanxi Kang, Jia Guo & Zhiwei Chen. (2013) Closing the door to human immunodeficiency virus. Protein & Cell 4:2, pages 86-102.
Crossref
Crossref
Annette N. Ratcliff, Wuxian Shi & Eric J. Arts. (2013) HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120. Journal of Virology 87:2, pages 923-934.
Crossref
Crossref
Piotr Pulik & Andrzej Horban. (2013) Komentarz do rekomendacji PTN AIDS 2013 – rozpoczynanie i monitorowanie leczenia antyretrowirusowego. HIV & AIDS Review 12:4, pages 109-112.
Crossref
Crossref
Christoph Stephan, Andrew Hill, Ning Xi, Yvon van Delft & Christiane Moecklinghoff. (2012) Research Letter. JAIDS Journal of Acquired Immune Deficiency Syndromes 61:5, pages e73-e75.
Crossref
Crossref
Lise Cuzin, Selma Trabelsi, Pierre Delobel, Claudine Barbuat, Jacques Reynes, Clotilde Allavena, Gilles Peytavin, Jade Ghosn, Caroline Lascoux-Combe, Christina Psomas, Pierre Corbeau & Philippe Flandre. (2012) Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration. JAIDS Journal of Acquired Immune Deficiency Syndromes 61:5, pages 557-564.
Crossref
Crossref
Victor G. Kramer, Susan M. Schader, Maureen Oliveira, Susan P. Colby-Germinario, Daniel A. Donahue, Diane N. Singhroy, Randy Tressler, Richard D. Sloan & Mark A. Wainberg. (2012) Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load. Antimicrobial Agents and Chemotherapy 56:8, pages 4154-4160.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
G. Fatkenheuer, C. Duvivier, A. Rieger, J. Durant, D. Rey, W. Schmidt, A. Hill, Y. van Delft, S. Marks, A. Rieger, N. Vetter, R. Greil, C. Pedersen, M. Storgaard, P. Morlat, C. Katlama, J. Durant, L. Cotte, C. Duvvier, D. Rey, S. Esser, C. Stellbrink, W. Schmidt, M. Stoll, C. Stephan, G. Fatkenheuer, A. Stoehr, J. Rockstroh, D. Banhegyi, L. Itzchak, E. Shahar, S. Maayan, D. Turner, A. Lazzarin, A. Antinori, G. Carosi, L. Minoli, G. di Perri, G. Filice, M. Andreoni, D. Duiculescu, S. Rugina, S. Erscoiu, A. Streinu, A. Pronin, V. Pokrovsky, B. Gruzdev, A. Yakovlev, E. Voronin, B. Clotet, J. Gatell, J. Arribas, D. Podzamczer, P. Domingo, C. Miralles Alvarez, J. Hernandez Quero, H. Furrer, J. Feher, M. Johnson, J. Fox, M. Nelson, M. Fisher & C. Orkin. (2011) Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. Journal of Antimicrobial Chemotherapy 67:3, pages 685-690.
Crossref
Crossref
Timothy J. WilkinRoy M. Gulick. (2012) CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities. Annual Review of Medicine 63:1, pages 81-93.
Crossref
Crossref
Alondra López-Martínez, Nathan M. O´ Brien, Yanink Caro-Vega, Brenda Crabtree-Ramírez & Juan Sierra-Madero. (2012) Different Baseline Characteristics and Different Outcomes of HIV-Infected Patients Receiving HAART Through Clinical Trials Compared With Routine Care in Mexico. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, pages 155-160.
Crossref
Crossref
S. Bonora, A. Calcagno, C. Cometto, S. Fontana, D. Aguilar, A. D’Avolio, D. Gonzalez de Requena, A. Maiello, I. Dal Conte, A. Lucchini & G. Di Perri. (2011) Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. Infection 40:1, pages 69-75.
Crossref
Crossref
Beniam Ghebremedhin. (2012) Maraviroc in Antiretroviral-Naïve HIV-1 Patients. Infectious Diseases: Research and Treatment 5, pages IDRT.S7597.
Crossref
Crossref
Marilia Rita Pinzone, Michelino Di Rosa, Bruno Cacopardo & Giuseppe Nunnari. (2012) HIV RNA Suppression and Immune Restoration: Can We Do Better?. Clinical and Developmental Immunology 2012, pages 1-12.
Crossref
Crossref
L. Garvey, M. Nelson, N. Latch, O. W. Erlwein, J. M. Allsop, A. Mitchell, S. Kaye, V. Watson, D. Back, S. D. Taylor-Robinson & A. Winston. (2011) CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. Journal of Antimicrobial Chemotherapy 67:1, pages 206-212.
Crossref
Crossref
Ricardo Camacho & Eugénio Teófilo. (2011) Antiretroviral therapy in treatment-naïve patients with HIV infection. Current Opinion in HIV and AIDS 6, pages S3-S11.
Crossref
Crossref
Brian Gazzard, Claudine Duvivier, Christian Zagler, Antonella Castagna, Andrew Hill, Yvonne van Delft & Stephan Marks. (2011) Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients. AIDS 25:18, pages 2249-2258.
Crossref
Crossref
Ezequiel Ruiz-Mateos, Alejandro González-Serna, Miguel Genebat, Kawthar Machmach, Francesc Vidal, Ángeles Muñoz-Fernández, Sara Ferrando-Martinez & Manuel Leal. (2011) Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. Antimicrobial Agents and Chemotherapy 55:10, pages 4664-4669.
Crossref
Crossref
Fernando Lozano & Pere Domingo. (2011) Tratamiento antirretroviral de la infección por el VIH. Enfermedades Infecciosas y Microbiología Clínica 29:6, pages 455-465.
Crossref
Crossref
Pierre CorbeauJacques Reynes. (2011) Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 117:21, pages 5582-5590.
Crossref
Crossref
LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vézinet, B Clotet, A De Luca, S Dressler, F Garcia, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, JM Schapiro, V Soriano, A Sönnerborg, A-M Vandamme, C Verhofstede, H Walter, M Zazzi & CAB Boucher. (2011) European guidelines on the clinical management of HIV-1 tropism testing. The Lancet Infectious Diseases 11:5, pages 394-407.
Crossref
Crossref
Calvin Cohen, Richard Elion, Peter Ruane, David Shamblaw, Edwin DeJesus, Bruce Rashbaum, Steven L Chuck, Kitty Yale, Hui C Liu, David R Warren, Srinivasan Ramanathan & Brian P Kearney. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:6, pages F7-F12.
Crossref
Crossref